National Biologics Manufacturing Centre launched
The new centre will provide companies with open access facilities and expertise to help them develop, prove and commercialise new and improved processes and technologies for biologics manufacture.
The Centre for Process Innovation (CPI) has officially launched the new £38 million National Biologics Manufacturing Centre in Darlington, Co. Durham. The new centre will provide companies with open access facilities and expertise to help them develop, prove and commercialise new and improved processes and technologies for biologics manufacture.
Biopharmaceuticals are medicines produced through biotechnology, which represent the cutting-edge The National Biologics Manufacturing Centre was announced in 2012 as part of the UK strategy for life science. The strategy outlined a vision for the UK to be a global leader in the life science sector. The £38 million investment was made by the Department for Business Innovation and Skills through InnovateUK.
Launching the new Centre, Jo Johnson MP, Minister of State for Universities and Science said: “We want the UK to be the best place in Europe to innovate which is why we have invested in this new Centre to capitalise on the North East’s expertise in medicines manufacturing and strengthen the UK’s position as a global leader in life sciences. As part of our successful Catapult network, the centre will bridge the gap between business and academia and help to turn great ideas into commercial reality.”
Steve Bagshaw, CEO of FUJIFILM Diosynth Biotechnologies said: “The National Biologics Manufacturing Centre will provide a valuable resource for the biologics sector in the UK. The centre will help the UK capture more of the expanding global market in high value, high quality manufacture of biologic medicines and make an important contribution to equipping the UK workforce to meet the challenges faced in this sector”.
Chris Dowle, Director of Biologics at CPI added: “CPI is supporting the commercialisation of research by promoting collaboration with industry across the supply chain, from research through to manufacture and clinic. Utilising the new Centre we will help companies to commercialise ideas and take them to market faster and with less risk. We are already underway with a number of projects which are helping UK companies prove their technologies in an industrially relevant environment.”
Ruth McKernan, Chief Executive of Innovate UK, said: “This new biologics manufacturing facility will be an important addition to CPI’s world-class capabilities in high value manufacturing. It will also work closely with our ground-breaking three healthcare Catapults and keep the UK at the forefront of a sector we have long excelled in.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance